{{Rsnum
|rsid=11615
|Gene=ERCC1
|Chromosome=19
|position=45420395
|Orientation=minus
|GMAF=0.3627
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ERCC1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 8.8 | 54.0 | 37.2
| HCB | 58.1 | 35.3 | 6.6
| JPT | 47.8 | 43.4 | 8.8
| YRI | 95.9 | 4.1 | 0.0
| ASW | 77.2 | 22.8 | 0.0
| CHB | 58.1 | 35.3 | 6.6
| CHD | 50.9 | 38.0 | 11.1
| GIH | 25.0 | 48.0 | 27.0
| LWK | 94.4 | 5.6 | 0.0
| MEX | 57.9 | 33.3 | 8.8
| MKK | 64.7 | 30.8 | 4.5
| TSI | 19.6 | 49.0 | 31.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11615
|Name_s=ERCC1:Asn118Asn; ERCC1:19007T>C;
|Gene_s=ERCC1
|Feature=
|Evidence=PubMed ID:19362955
|Annotation=Risk or phenotype-associated allele: C. Phenotype: In a study of patients with NSCLC carriers of the C variant of ERCC1:Asn118Asn were more likely to respond to platinum-based chemotherapy compared with those without the C allele. Study size: 119. Study population/ethnicity: Patients with NSCLC treated with platinum-based regimens as first- or second-line chemotherapy. Significance metric(s): OR = 0.10; 95% CI, 0.013-0.828; p = 0.033. Type of association: CO.
|Drugs=platinum
|Drug Classes=
|Diseases=Carcinoma, Non-Small-Cell Lung
|Curation Level=Curated
|PharmGKB Accession ID=PA165109243
}}

{{PharmGKB
|RSID=rs11615
|Name_s=ERCC1:19007T>C; ERCC1:Asn118Asn
|Gene_s=ERCC1
|Feature=
|Evidence=PubMed ID:19786980
|Annotation=In a study of ovarian cancer patients (n=104) receiving a cisplatin-cyclophosphamide regimen, the heterozygous T/C genotype of ERCC1:19007T>C was associated with nephrotoxicity.
|Drugs=cisplatin; cyclophosphamide
|Drug Classes=
|Diseases=nephrotoxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165107202
}}

{{PMID Auto
|PMID=21739480
|Title=Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: A pathway-based analysis
}}

{{PMID Auto
|PMID=21826087
|Title=Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy
|OA=1
}}

{{PMID|15734977}} Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.

{{PMID|17299578|OA=1
}} Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis.

{{PMID|18332046}} A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients.

{{PMID|18544627|OA=1
}} Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk.

{{PMID|18635523|OA=1
}} Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis.

{{PMID|18990748|OA=1
}} International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways.

{{PMID|19361884}} Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.

{{PMID|19536092|OA=1
}} Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.

{{PMID|20003391|OA=1
}} ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females.

{{PMID|20003463|OA=1
}} Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.

{{PMID|21278243|OA=1
}} ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.

{{PMID|21315089|OA=1
}} The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.

{{PMID|21364592|OA=1
}} CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.

{{PMID|21553053}} The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer.

{{PMID|21601580}} HapMap-based study of a region encompassing ERCC1 and ERCC2 related to lung cancer susceptibility in a Chinese population.

{{PMID|21956434}} Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.

{{PMID|22002622}} Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis.

{{PMID|22201261}} ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospital-based case-control study.

{{PMID|22335888}} A specific diplotype defined by PPP1R13L rs1970764, CD3EAP rs967591 and ERCC1 rs11615 and lung cancer risk in a Chinese population.

{{PMID Auto
|PMID=23166636
|Title=Polymorphisms in ERCC1 and XPF Genes and Risk of Gastric Cancer in an Eastern Chinese Population
|OA=1
}}

{{PMID Auto
|PMID=23147699
|Title=Association of genetic polymorphisms in ERCC1 and ERCC2/XPD with risk of chronic benzene poisoning in a Chinese occupational population
}}

{{PMID Auto
|PMID=23680703
|Title=A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population
}}

{{PMID Auto
|PMID=23684781
|Title=Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity
}}

{{PMID Auto
|PMID=23909490
|Title=Polymorphisms in the ERCC1 and XPF Genes and Risk of Breast Cancer in a Chinese Population
}}

{{PMID Auto
|PMID=23936089
|Title=Polymorphisms in DNA-Repair Genes in a Cohort of Prostate Cancer Patients from Different Areas in Spain: Heterogeneity between Populations as a Confounding Factor in Association Studies
|OA=1
}}

{{PMID Auto
|PMID=23962907
|Title=ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy
}}

{{PMID Auto
|PMID=24103542
|Title=High-throughput genotyping system as a robust and useful tool in oncology: Experience from a single institution
}}

{{PMID Auto
|PMID=24325908
|Title=Analysis of dna repair gene polymorphisms in glioblastoma
}}

{{PMID Auto
|PMID=24499239
|Title=Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis
}}

{{PMID Auto
|PMID=22821389
|Title=Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.
}}

{{PMID Auto
|PMID=23175176
|Title=Variation in PAH-related DNA adduct levels among non-smokers: the role of multiple genetic polymorphisms and nucleotide excision repair phenotype.
}}

{{PMID Auto
|PMID=23180017
|Title=PPP1R13L variant associated with prognosis for patients with rectal cancer.
}}

{{PMID Auto
|PMID=23203453
|Title=Excision repair of BPDE-adducts in human lymphocytes: diminished capacity associated with ERCC1 C8092A (rs3212986) polymorphism.
}}

{{PMID Auto
|PMID=24859833
|Title=Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients
}}

{{PMID Auto
|PMID=24861646
|Title=Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use
}}

{{PMID Auto
|PMID=24939416
|Title=CYP1A1 Ile462Val polymorphism and colorectal cancer risk in Polish patients
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}